Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes. Issue 9 (27th June 2015)

• Record Type: Journal Article
• Authors: Inzucchi, S. E.; Nauck, M. A.; Hehnke, U.; Woerle, H.‐J.; von Eynatten, M.; Henry, R. R.
• Is Part Of: Diabetes, obesity & metabolism. Volume 17:Issue 9(2015:Sep.)
• Page Start: 868
• Page End: 877
• Publication Date: 2015-06-27
• Subjects: Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.12490
• Languages: English
• ISSNs: 1462-8902

Abstract

<abstract abstract-type="main" id="dom12490-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="dom12490-sec-0001" sec-type="section"> <title>Aim</title> <p id="dom12490-para-0001">To assess the efficacy, hypoglycaemia risk and other safety markers of linagliptin as an additional therapy in older patients (aged ≥70 years) inadequately controlled with basal insulin.</p> </sec> <sec id="dom12490-sec-0002" sec-type="section"> <title>Methods</title> <p id="dom12490-para-0002">A prespecified safety analysis from the linagliptin trials programme was carried out to explore the hypoglycaemia risk when linagliptin was added to background basal insulin therapy in elderly patients (≥70 years). To do this, two eligible, randomized, placebo‐controlled, clinical trials (NCT00954447 and NCT01084005) of 24 and ≥52 weeks, respectively, were analysed.</p> </sec> <sec id="dom12490-sec-0003" sec-type="section"> <title>Results</title> <p id="dom12490-para-0003">A total of 247 elderly individuals [mean ± standard deviation (s.d.) age 74 ± 4 years, glycated haemoglobin (HbA1c) 8.2 ± 0.8%] on basal insulin (mean ± s.d. baseline dose 36 ± 25 IU/day) were identified. Alongside placebo‐adjusted change in HbA1c with linagliptin of −0.77% [95% confidence interval (CI) −0.95 to 0.59; p < 0.0001] after 24 weeks, the hazard ratios (HRs) of both overall and confirmed hypoglycaemia [blood glucose ≤3.9 mmol/l (70 mg/dl)], were significantly lower with linagliptin than with placebo: HR 0.61 (95% CI 0.39–0.97) versus 0.59 (95% CI 0.37–0.94), respectively (both p < 0.05). Moreover, significantly less confirmed hypoglycaemia was present in linagliptin‐treated patients with renal impairment [HR 0.45 (95% CI 0.27–0.76)], moderate hyperglycaemia [HbA1c 7.5 to <9.0%; HR 0.51 (95% CI 0.27–0.99)], lower fasting plasma glucose levels [<152 mg/dl; HR 0.49 (95% CI 0.28–0.86)] and those treated with higher insulin doses [insulin ≥35.6 IU/day; HR 0.46 (95% CI 0.23–0.91); p < 0.05 for all]. Severe hypoglycaemia was rare and the incidence was lower with linagliptin (0.8%) versus placebo (2.5%): HR 0.21 (95% CI 0.02–2.30).</p> </sec> <sec id="dom12490-sec-0004" sec-type="section"> <title>Conclusions</title> <p id="dom12490-para-0004">Despite improvements in hyperglycaemia and no relevant on‐trial insulin dose reductions, adding linagliptin to basal insulin appears to decrease hypoglycaemia risk. The biological basis of this phenomenon warrants further research but may involve counter‐regulatory effects of incretin hormones.</p> </sec> </abstract>